Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMP NASDAQ:CRVS NASDAQ:MTCR NASDAQ:NERV NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsCRVSCorvus Pharmaceuticals$5.74-2.4%$4.97$2.54▼$10.00$438.14M0.52546,557 shs383,550 shsMTCRMetacrine$0.58$0.57$0.30▼$0.59$24.75M-0.73225,834 shs83,889 shsNERVMinerva Neurosciences$2.16-4.0%$2.08$1.15▼$2.98N/A-0.2512,565 shs25,382 shsSVRASavara$3.63+0.6%$2.93$1.89▼$4.70$623.94M0.561.73 million shs1.07 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRVSCorvus Pharmaceuticals+0.86%-0.34%+8.29%+49.24%+15.29%MTCRMetacrine0.00%0.00%0.00%0.00%0.00%NERVMinerva Neurosciences+4.90%+3.69%0.00%+22.28%-23.73%SVRASavara+1.40%-6.23%+18.75%+76.96%-14.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsCRVSCorvus Pharmaceuticals$5.74-2.4%$4.97$2.54▼$10.00$438.14M0.52546,557 shs383,550 shsMTCRMetacrine$0.58$0.57$0.30▼$0.59$24.75M-0.73225,834 shs83,889 shsNERVMinerva Neurosciences$2.16-4.0%$2.08$1.15▼$2.98N/A-0.2512,565 shs25,382 shsSVRASavara$3.63+0.6%$2.93$1.89▼$4.70$623.94M0.561.73 million shs1.07 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRVSCorvus Pharmaceuticals+0.86%-0.34%+8.29%+49.24%+15.29%MTCRMetacrine0.00%0.00%0.00%0.00%0.00%NERVMinerva Neurosciences+4.90%+3.69%0.00%+22.28%-23.73%SVRASavara+1.40%-6.23%+18.75%+76.96%-14.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis Pharmaceuticals 0.00N/AN/AN/ACRVSCorvus Pharmaceuticals 3.00Buy$13.00126.48% UpsideMTCRMetacrine 0.00N/AN/AN/ANERVMinerva Neurosciences 2.00Hold$5.00131.48% UpsideSVRASavara 2.83Moderate Buy$7.50106.61% UpsideCurrent Analyst Ratings BreakdownLatest SVRA, NERV, ADMP, CRVS, and MTCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.009/8/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $8.009/3/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.008/15/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.008/15/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.00 ➝ $5.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00CRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/AMTCRMetacrineN/AN/AN/AN/A$1.36 per shareN/ANERVMinerva NeurosciencesN/AN/A$0.20 per share10.77($3.67) per shareN/ASVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/ACRVSCorvus Pharmaceuticals-$62.29M-$1.01N/AN/AN/AN/A-28.61%-18.05%11/11/2025 (Estimated)MTCRMetacrine-$62.21M-$1.03N/A∞N/AN/A-84.88%-59.33%N/ANERVMinerva Neurosciences$1.44M$1.481.46N/AN/AN/A-41.35%31.37%11/4/2025 (Estimated)SVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest SVRA, NERV, ADMP, CRVS, and MTCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025NERVMinerva Neurosciences-$0.95-$0.43+$0.52-$0.43N/AN/A8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/7/2025Q2 2025CRVSCorvus Pharmaceuticals-$0.13-$0.10+$0.03-$0.10N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AMTCRMetacrineN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19CRVSCorvus PharmaceuticalsN/A8.918.91MTCRMetacrine0.3412.1512.15NERVMinerva NeurosciencesN/A6.156.15SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%CRVSCorvus Pharmaceuticals46.64%MTCRMetacrine37.72%NERVMinerva Neurosciences34.56%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%CRVSCorvus Pharmaceuticals31.30%MTCRMetacrine13.80%NERVMinerva Neurosciences8.60%SVRASavara5.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableCRVSCorvus Pharmaceuticals3074.51 million51.19 millionOptionableMTCRMetacrine1042.57 million36.70 millionNot OptionableNERVMinerva Neurosciences9N/AN/ANot OptionableSVRASavara20172.84 million163.97 millionOptionableSVRA, NERV, ADMP, CRVS, and MTCR HeadlinesRecent News About These CompaniesDid You Lose Money in SVRA? Shareholders Who Lost Money in SVRA Should Contact Robbins LLP for Information About the Savara Inc. Securities Class Action Lawsuit3 hours ago | prnewswire.comSVRA Investors have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit4 hours ago | prnewswire.comRosen Law Firm Urges Savara Inc. (NASDAQ: SVRA) Stockholders with Large Losses to Contact the Firm for Information About Their RightsSeptember 16 at 6:00 PM | businesswire.comSavara Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights – SVRASeptember 16 at 5:18 PM | globenewswire.comKirby McInerney LLP Reminds Savara Inc. Investors of Class Action Filing and Encourages Investors to Contact the FirmSeptember 16 at 2:32 PM | globenewswire.comDeadline Approaching: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. SmithSeptember 16 at 2:22 PM | businesswire.comSVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 16 at 12:00 PM | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRASeptember 16 at 10:06 AM | theglobeandmail.comNovember 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRASeptember 16 at 8:45 AM | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRASeptember 15 at 3:50 PM | globenewswire.comLaw Offices of Frank R. Cruz Encourages Savara Inc. (SVRA) Investors To Inquire About Securities Fraud Class ActionSeptember 15 at 12:07 PM | businesswire.comSavara Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights - SVRASeptember 15 at 8:45 AM | prnewswire.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 15 at 5:08 AM | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRASeptember 14 at 10:00 AM | globenewswire.comSavara (NASDAQ:SVRA) Stock Price Down 3.3% - Should You Sell?September 13 at 2:11 PM | marketbeat.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRASeptember 13 at 10:00 AM | prnewswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Savara Inc. (SVRA) Investors to Inquire About Securities Fraud Class ActionSeptember 12, 2025 | tmcnet.comSVRA Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Savara Inc. Securities Class Action LawsuitSeptember 12, 2025 | globenewswire.comSVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 12, 2025 | prnewswire.comPortnoy Law Firm Announces Class Action on Behalf of Savara, Inc. InvestorsSeptember 11, 2025 | globenewswire.comLaw Offices of Howard G. Smith Encourages Savara Inc. (SVRA) Investors To Inquire About Securities Fraud Class ActionSeptember 11, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSVRA, NERV, ADMP, CRVS, and MTCR Company DescriptionsAdamis Pharmaceuticals NASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Corvus Pharmaceuticals NASDAQ:CRVS$5.74 -0.14 (-2.38%) Closing price 04:00 PM EasternExtended Trading$5.80 +0.06 (+1.11%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Metacrine NASDAQ:MTCRMetacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Minerva Neurosciences NASDAQ:NERV$2.16 -0.09 (-4.00%) Closing price 04:00 PM EasternExtended Trading$2.16 0.00 (0.00%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Savara NASDAQ:SVRA$3.63 +0.02 (+0.55%) Closing price 04:00 PM EasternExtended Trading$3.38 -0.25 (-6.89%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
